I think that researchers tend to be very imaginative and carrots tend to work very well. You do control funding. If you decide that removing red tape is a valuable thing to do, you can work on it inside Ottawa, but also you could present funding opportunities that have to be interprovincial and address major issues surrounding the personalization of health care. Then you're harnessing the imaginations of a large number of other people to try to find solutions.
In the drug-approval space this is something that is inside your domain where you could make a huge difference and work with the community to reshape drug approvals surrounding personalized medicine indications. There are a lot of people who have probably spoken with your group and others, such as Janet Dancey from the Ontario Institute for Cancer Research, and individuals from the National Cancer Institute of Canada Clinical Trials Group, about how we need to rethink drug approvals. It could make a huge difference.
Things don't have to be completely approved. They could be approved for on-the-ground study without having a global approval. There would be different ways of looking at this.
But in the funding domain, if opportunities were presented that encourage people to work together between provinces you would see solutions coming out of that.